Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Microarray In Node negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy - A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. (EORTC Protocol 10041 – BIG 3-04).

Trial Profile

Microarray In Node negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy - A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. (EORTC Protocol 10041 – BIG 3-04).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary) ; Anthracyclines
  • Indications Early breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MINDACT
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Dec 2017 Results related to MammaPrint assessment published in an Agendia media release.
    • 12 Dec 2017 According to an Agendia media release, data from the study has been presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top